Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396236 · ClinicalTrials.gov registry record · Phase 3
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 851
- Enrollment target
NCT04396236 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 851 participants.
The verdict
NCT04396236, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 851 participants
- Enrollment target
Study Summary
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Interventions
- DRUG Placebo
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 851 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2025-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04396236
The ClinicalTrials.gov registry entry for NCT04396236 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 851 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04396236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04396236 about?
NCT04396236 is a clinical study titled "A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine". The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
What is the current status of trial NCT04396236?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 851 participants. The study started on 2020-06-15. Estimated completion is 2025-11-12.
What interventions are being tested in trial NCT04396236?
The interventions under investigation include: Placebo (DRUG), Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT04396236?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.